Beth Israel Deaconess Medical Center Initiates Evaluation of Aastrom Biosciences' New Dendritic Cell Vaccine Product for Cancer

- Product Testing Begins at Second Major Cancer Center -



Apr 16, 2001, 01:00 ET from Aastrom Biosciences, Inc.

    ANN ARBOR, Mich., April 16 /PRNewswire Interactive News Release/ --
 Aastrom Biosciences, Inc. (Nasdaq:   ASTM) announced today that it has
 formalized an agreement with Beth Israel Deaconess Medical Center (BIDMC),
 Boston, MA to conduct external clinical beta site evaluations of Aastrom's new
 DC-I dendritic cell product for use in vaccines to treat various forms of
 cancer.  BIDMC, a Harvard Medical School teaching hospital, becomes the second
 major cancer center in the U.S. to begin product testing following the recent
 announcement of similar activities initiated at the Barbara Ann Karmanos
 Cancer Institute at Wayne State University, Detroit, MI.  BIDMC will conduct
 the evaluation in conjunction with the Dana-Farber Cancer Institute.
     As Aastrom expands its clinical beta site program, the Company moves
 closer to attaining an important objective of making its dendritic cell
 product broadly available for dendritic cell-based cancer vaccines.  Aastrom
 intends to apply for CE Mark approval necessary for European marketing once
 the DC-I dendritic cell product receives validation from external evaluations.
 Aastrom intends to also market the DC-I cell product to leading U.S. clinical
 and research groups that are developing dendritic cell-based cancer vaccines.
 These novel therapies are becoming important new therapeutic approaches in the
 treatment of cancer.
     "The expansion of our dendritic cell program to BIDMC moves Aastrom an
 important step forward in our plan to commercialize the DC-I product in Europe
 during 2001," stated R. Douglas Armstrong, Ph.D., President and CEO of
 Aastrom.  "We are strategically positioning Aastrom to become a leading
 provider of cell-based therapeutics.  The DC-I cell product is targeted at a
 large market in Europe and the U.S., and Aastrom intends to deliver the
 highest quality dendritic cell product to sites developing or using dendritic
 cell-based vaccines for the treatment of cancer."
     Aastrom selected researchers at BIDMC as its second U.S. collaborator
 because of its dendritic cell vaccine expertise.  Aastrom's DC-I dendritic
 cell product is intended to provide a highly active and reliable source of
 dendritic cells for the types of clinical procedures that are being done at
 BIDMC.  Pending a successful outcome of beta site testing by BIDMC, Aastrom
 intends to integrate the AastromReplicell(TM) System into various clinical
 trial programs.
     Dendritic cell-based treatments and vaccines are being widely pursued
 throughout the world as new therapeutic approaches for treating certain viral
 diseases and cancers, including breast cancer, renal cell carcinoma and
 melanoma.  The American Cancer Society estimates that these cancers affect
 more than 250,000 new patients annually.
     Aastrom is pioneering the development of proprietary cell therapeutics and
 cell products based on its dual-technology platforms: patented "single-pass
 perfusion" providing cells with enhanced biological function, and patented
 GMP-compliant system automation facilitating the delivery of cells for
 therapeutic use into medical practice.  These technologies are integrated into
 the AastromReplicell(TM) System that is designed to uniquely standardize and
 automate the processes involved in producing high quality therapeutic cells.
 Aastrom is developing the DC-I dendritic cell product for use in the rapidly
 emerging cancer vaccine market and the OC-I bone progenitor cell product for
 the treatment of degenerative bone diseases such as osteoporosis.  The
 AastromReplicell(TM) System, the SC-I bone marrow stem cell product and the
 CB-I cord blood stem cell product have received CE Mark approval necessary for
 European marketing and are in late-stage U.S. clinical trials.  These products
 are not available for sale at this time in the U.S., except for research or
 investigational use.
     Please visit our website at http://www.aastrom.com
 
     This document contains forward-looking statements, including without
 limitation, statements concerning intended areas of research, product
 development objectives, clinical trial results, commercialization plans,
 potential product applications, and potential advantages of the
 AastromReplicellTM System, which involve certain risks and uncertainties.  The
 forward-looking statements are also identified through use of the words
 "intends," "plan," and other words of similar meaning.  Actual results may
 differ significantly from the expectations contained in the forward-looking
 statements.  Among the factors that may result in differences are the results
 obtained from clinical trial and product development activities, regulatory
 approval requirements, the availability of resources, competitive
 developments, the availability of resources and the allocation of resources
 among different potential uses.  These and other significant factors are
 discussed in greater detail in Aastrom's Annual Report on Form-10K and other
 filings with the Securities and Exchange Commission.
 
     CONTACT:  Todd E. Simpson, VP Finance & Administration, CFO, of Aastrom
 Biosciences, Inc., 734-930-5777; or Hala Bashir, media,
 212-696-4455, ext. 356, or David Walsey, investors, 212-696-4455 ext. 230,
 both of Noonan/Russo Communications, Inc., for Aastrom Biosciences, Inc.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X57029462
 
 

SOURCE Aastrom Biosciences, Inc.
    ANN ARBOR, Mich., April 16 /PRNewswire Interactive News Release/ --
 Aastrom Biosciences, Inc. (Nasdaq:   ASTM) announced today that it has
 formalized an agreement with Beth Israel Deaconess Medical Center (BIDMC),
 Boston, MA to conduct external clinical beta site evaluations of Aastrom's new
 DC-I dendritic cell product for use in vaccines to treat various forms of
 cancer.  BIDMC, a Harvard Medical School teaching hospital, becomes the second
 major cancer center in the U.S. to begin product testing following the recent
 announcement of similar activities initiated at the Barbara Ann Karmanos
 Cancer Institute at Wayne State University, Detroit, MI.  BIDMC will conduct
 the evaluation in conjunction with the Dana-Farber Cancer Institute.
     As Aastrom expands its clinical beta site program, the Company moves
 closer to attaining an important objective of making its dendritic cell
 product broadly available for dendritic cell-based cancer vaccines.  Aastrom
 intends to apply for CE Mark approval necessary for European marketing once
 the DC-I dendritic cell product receives validation from external evaluations.
 Aastrom intends to also market the DC-I cell product to leading U.S. clinical
 and research groups that are developing dendritic cell-based cancer vaccines.
 These novel therapies are becoming important new therapeutic approaches in the
 treatment of cancer.
     "The expansion of our dendritic cell program to BIDMC moves Aastrom an
 important step forward in our plan to commercialize the DC-I product in Europe
 during 2001," stated R. Douglas Armstrong, Ph.D., President and CEO of
 Aastrom.  "We are strategically positioning Aastrom to become a leading
 provider of cell-based therapeutics.  The DC-I cell product is targeted at a
 large market in Europe and the U.S., and Aastrom intends to deliver the
 highest quality dendritic cell product to sites developing or using dendritic
 cell-based vaccines for the treatment of cancer."
     Aastrom selected researchers at BIDMC as its second U.S. collaborator
 because of its dendritic cell vaccine expertise.  Aastrom's DC-I dendritic
 cell product is intended to provide a highly active and reliable source of
 dendritic cells for the types of clinical procedures that are being done at
 BIDMC.  Pending a successful outcome of beta site testing by BIDMC, Aastrom
 intends to integrate the AastromReplicell(TM) System into various clinical
 trial programs.
     Dendritic cell-based treatments and vaccines are being widely pursued
 throughout the world as new therapeutic approaches for treating certain viral
 diseases and cancers, including breast cancer, renal cell carcinoma and
 melanoma.  The American Cancer Society estimates that these cancers affect
 more than 250,000 new patients annually.
     Aastrom is pioneering the development of proprietary cell therapeutics and
 cell products based on its dual-technology platforms: patented "single-pass
 perfusion" providing cells with enhanced biological function, and patented
 GMP-compliant system automation facilitating the delivery of cells for
 therapeutic use into medical practice.  These technologies are integrated into
 the AastromReplicell(TM) System that is designed to uniquely standardize and
 automate the processes involved in producing high quality therapeutic cells.
 Aastrom is developing the DC-I dendritic cell product for use in the rapidly
 emerging cancer vaccine market and the OC-I bone progenitor cell product for
 the treatment of degenerative bone diseases such as osteoporosis.  The
 AastromReplicell(TM) System, the SC-I bone marrow stem cell product and the
 CB-I cord blood stem cell product have received CE Mark approval necessary for
 European marketing and are in late-stage U.S. clinical trials.  These products
 are not available for sale at this time in the U.S., except for research or
 investigational use.
     Please visit our website at http://www.aastrom.com
 
     This document contains forward-looking statements, including without
 limitation, statements concerning intended areas of research, product
 development objectives, clinical trial results, commercialization plans,
 potential product applications, and potential advantages of the
 AastromReplicellTM System, which involve certain risks and uncertainties.  The
 forward-looking statements are also identified through use of the words
 "intends," "plan," and other words of similar meaning.  Actual results may
 differ significantly from the expectations contained in the forward-looking
 statements.  Among the factors that may result in differences are the results
 obtained from clinical trial and product development activities, regulatory
 approval requirements, the availability of resources, competitive
 developments, the availability of resources and the allocation of resources
 among different potential uses.  These and other significant factors are
 discussed in greater detail in Aastrom's Annual Report on Form-10K and other
 filings with the Securities and Exchange Commission.
 
     CONTACT:  Todd E. Simpson, VP Finance & Administration, CFO, of Aastrom
 Biosciences, Inc., 734-930-5777; or Hala Bashir, media,
 212-696-4455, ext. 356, or David Walsey, investors, 212-696-4455 ext. 230,
 both of Noonan/Russo Communications, Inc., for Aastrom Biosciences, Inc.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X57029462
 
 SOURCE  Aastrom Biosciences, Inc.